| 产品描述: | CB 1954是用于基因疗法研究的前药,并被NAD(P)H醌氧化还原酶激活。 |
| 体内研究: |
Tretazicar (CB 1954) (80 mg/kg;腹腔注射,第 2 天和第 9 天) 可显著提高存活率。 |
| 参考文献: |
1. Knox RJ,et al. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 2000 Aug 1;60(15):4179-86. 2. Knox RJ, et al. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des. 2003;9(26):2091-104. 3. Green NK, et al. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronicadenovirus vector. Int J Cancer. 2003 Mar 10;104(1):104-12. 4. Drabek D, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997 Feb;4(2):93-100. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.965 ml |
19.827 ml |
39.654 ml |
| 5 mM |
0.793 ml |
3.965 ml |
7.931 ml |
| 10 mM |
0.397 ml |
1.983 ml |
3.965 ml |
| 50 mM |
0.079 ml |
0.397 ml |
0.793 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |